Trade the Expected Move
Apr 17 • Expiry
BVS stock price in 30 days?
News
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know
Bioventus (BVS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com • Mar 17, 2025 13:00 Eastern
Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript
Bioventus Inc. (NASDAQ:BVS ) Q4 2024 Earnings Conference Call March 11, 2025 8:30 AM ET Company Participants Dave Crawford - Investor Relations Rob Claypoole - President & Chief Executive Officer Mark Singleton - Senior Vice President & Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Caitlin Cronin - Canaccord Genuity Operator Good morning and welcome to the Bioventus Fourth Quarter 2024 Earnings Conference Call. All participants will be in listen-only mode.
seekingalpha.com • Mar 11, 2025 14:31 Eastern
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million
On Tuesday, Bioventus Inc. BVS reported fourth-quarter adjusted EPS of 15 cents, up from 7 cents, beating the consensus of 8 cents.
benzinga.com • Mar 11, 2025 11:17 Eastern
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates
Bioventus (BVS) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.09 per share. This compares to earnings of $0.07 per share a year ago.
zacks.com • Mar 11, 2025 09:46 Eastern
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
DURHAM, N.C., March 11, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2024, and provided its financial guidance for full-year 2025.
globenewswire.com • Mar 11, 2025 07:30 Eastern
Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025
DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.
globenewswire.com • Feb 28, 2025 07:30 Eastern
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business
Bioventus aims to improve its focus and execution within its core businesses and enhance liquidity following the divestiture.
zacks.com • Jan 03, 2025 12:00 Eastern
Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners
DURHAM, N.C., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, announced today that it has successfully completed the divestiture of its Advanced Rehabilitation business to Accelmed Partners (“Accelmed”), a private equity firm focused on acquiring and growing commercial-stage HealthTech companies. The transaction, announced on October 1, 2024, enables Bioventus to continue improving its focus and execution within the Company's core businesses, while also delivering approximately $20 million of net closing proceeds to enhance liquidity.
globenewswire.com • Jan 02, 2025 08:00 Eastern